CRISPR accelerates the cancer drug discovery

Show full item record



Permalink

http://hdl.handle.net/10138/345845

Citation

Yang , R , Wang , J , Liu , M & Zhou , K 2022 , ' CRISPR accelerates the cancer drug discovery ' , Biocell , vol. 46 , no. 10 , pp. 2159-2165 . https://doi.org/10.32604/biocell.2022.021107

Title: CRISPR accelerates the cancer drug discovery
Author: Yang, Ruyu; Wang, Junjie; Liu, Minxia; Zhou, Kecheng
Contributor organization: Institute for Molecular Medicine Finland
Helsinki Institute of Life Science HiLIFE
Department of Anatomy
University of Helsinki
Faculty of Medicine
Date: 2022
Language: eng
Number of pages: 7
Belongs to series: Biocell
ISSN: 0327-9545
DOI: https://doi.org/10.32604/biocell.2022.021107
URI: http://hdl.handle.net/10138/345845
Abstract: Emerging cohorts and basic studies have associated certain genetic modifications in cancer patients, such as gene mutation, amplification, or deletion, with the overall survival prognosis, underscoring patients??? genetic background may directly regulate drug sensitivity/resistance during chemotherapies. Understanding the molecular mechanism underpinning drug sensitivity/resistance and further uncovering the effective drugs have been the major ambition in the cancer drug discovery. The emergence and popularity of CRISPR/Cas9 technology have reformed the entire life science research, providing a precise and simplified genome editing tool with unlimited editing possibilities. Furthermore, it presents a powerful tool in cancer drug discovery, which hopefully facilitates us with a rapid and reliable manner in developing novel therapies and understanding the molecular mechanisms of drug sensitivity/resistance. Herein, we summarized the application of CRISPR/Cas9 in drug screening, with the focus on CRISPR/Cas9 mediated gene knockout, gene knock-in, as well as transcriptional modification. Additionally, this review provides the concerns, cautions, and ethnic considerations that need to be taken when applying CRISPR in the drug discovery.
Subject: CRISPR
Cas9
Cancer drug discovery
Drug sensitivity
Resistance
Novel cancer therapies
TRANSCRIPTIONAL ACTIVATION
GENOME
CLASSIFICATION
3111 Biomedicine
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
20220613135247_79274.pdf 1001.Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record